Nasdaq Falls 100 Points; Siyata Mobile Shares Spike Higher
Portfolio Pulse from Lisa Levin
US stocks traded lower with the Nasdaq Composite falling over 100 points. The Home Depot reported better-than-expected Q2 results and authorized a new $15 billion share repurchase program. Delcath Systems, Novo Integrated Sciences, and Siyata Mobile saw their shares rise after positive news. F45 Training Holdings, Design Therapeutics, and Galecto saw their shares drop after negative news.
August 15, 2023 | 7:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Delcath Systems shares shot up after the company announced FDA approval of HEPZATO KIT for the treatment of adult patients with unresectable hepatic-dominant metastatic uveal melanoma.
The FDA approval of HEPZATO KIT is a major positive development for Delcath Systems and could lead to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Home Depot reported better-than-expected Q2 results and authorized a new $15 billion share repurchase program.
The better-than-expected results and the new share repurchase program are positive news for Home Depot and could lead to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Novo Integrated Sciences shares got a boost after the company and Farm 7 Group announced a joint venture for Kenya Agricultural Cooperative Project.
The joint venture for Kenya Agricultural Cooperative Project is a positive development for Novo Integrated Sciences and could lead to a short-term increase in its stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Siyata Mobile shares were up following upbeat quarterly sales.
The upbeat quarterly sales are a positive development for Siyata Mobile and could lead to a short-term increase in its stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Design Therapeutics shares were down after the company reported initial results from its Phase 1 multiple-ascending dose study of DT-216 for the treatment of Friedrich ataxia.
The initial results from the Phase 1 study of DT-216 are a negative development for Design Therapeutics and could lead to a short-term decrease in its stock price.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
F45 Training Holdings shares dropped after the company announced it intends to voluntarily delist and deregister its securities.
The announcement to voluntarily delist and deregister its securities is a negative development for F45 Training Holdings and could lead to a short-term decrease in its stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Galecto shares were down after the company announced topline results from its Phase 2b GALACTIC-1 trial of GB0139 for idiopathic pulmonary fibrosis, which showed the trial did not meet its primary endpoint.
The failure to meet the primary endpoint in the Phase 2b GALACTIC-1 trial of GB0139 is a negative development for Galecto and could lead to a short-term decrease in its stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100